Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and efficacy concerns in the U.S. after being selected for the FDA Commissioner’s National Priority Review vouchers last
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers
